CD19 and B-cell chronic lymphocytic leukemia: Clinical research that took place at the University of Pennsylvania as pioneering research, which showcased notable success in treating refractory advanced chronic lymphocytic leukemia (CLL) with the aid of using anti-CD19 CAR T cells, causing two complete responses in each of the three afflicted people.